Pets clause samples

Our growth depends, in part, on our ability to successfully introduce new products and product line extensions and improve and reposition our existing products to meet the requirements of pet parents and the dietary needs of their pets. This, in turn, depends on our ability to predict and respond to evolving consumer trends, demands and preferences. The development and introduction of innovative new products and product line extensions involve considerable costs. In addition, it may be difficult to establish new supplier relationships and determine appropriate product selection when developing a new product or product line extension. Any new product or product line extension may not generate sufficient customer interest and sales to become a profitable product or to cover the costs of its development and promotion and may reduce our operating income. In addition, any such unsuccessful effort may adversely affect our brand. If we are not able to anticipate, identify or develop and market products that respond to changes in requirements and preferences of pet parents and their pets or if our new product introductions or repositioned products fail to gain consumer acceptance, we may not grow our business as anticipated, our sales may decline and our business, financial condition and results of operations may be materially adversely affected.

True Leaf is a plant-forward wellness brand for people and their pets. Founded in 2013, True Leaf has two main operating divisions: True Leaf Medicine Inc. and True Leaf Pet Inc.

Established in 2015, True Leaf Pet Inc. is one of the first companies to market hemp-based products for pets worldwide. The Company is initially marketing a line of hemp-seed based supplements for pets. True Hemp™ chews, dental sticks, and supplement oils are sold in more than 2,000 stores across North America and Europe.

True Leaf is a leading global cannabis and hemp wellness brand for pets. Inspired by the unconditional love our pets give us every day, we return that love through our wellness pet products which help maintain and protect the natural vitality of our pet companions. “Return the Love” is the purpose that drives our business and is at the heart of our values to bring happiness to pets and their owners.

As Chair of True Leaf’s Veterinary Advisory Board, Dr. Kramer will recruit veterinarians from around the world to join True Leaf as the company develops legal and safe medicinal cannabis products for pets. She and her colleagues will be instrumental in the research and development of CBD pet products at True Leaf, including the design and execution of supportive trials and the development of education programs for veterinarians and pet owners on the best use of cannabis products for pets.

With the proposed legalization of cannabis, Canadian pet owners will have the opportunity to explore the use of cannabis for their pets. Similar to the human medical market; high quality, pharmaceutical-grade cannabis products can be an integral option in supporting the overall health and well-being of pets.

This new partnership will couple CannTrusts’ trailblazing expertise in medical cannabis with Grey Wolf’s deep veterinary experience, giving pet owners a trusted avenue to support the well-being of their beloved pets. Under the terms of the partnership, Grey Wolf and CannTrust will be equal partners in a newly created subsidiary of Grey Wolf. In addition, CannTrust will upon the exercise of share purchase warrants, become a substantial shareholder in Grey Wolf.

“CannTrust is delighted to partner with Grey Wolf in the development of medical cannabis products for the Global pet market. This is a key step in our strategy to expand our best-in -class products and technology into adjacent categories. We look forward to launching, together with Grey Wolf, industry leading, high quality, standardized cannabis products specifically designed for pets.” said Eric Paul, CEO of CannTrust.

“CannTrust is the ideal partner for Grey Wolf. We believe that CannTrust’s best practices in manufacturing pharmaceutical-grade products, distribution and practitioner education programs in the human medical cannabis market complements our expertise in the veterinary market to place us at the forefront of cannabis for pets.” said Dr. Ian Sandler, CEO of Grey Wolf.

On April 18, 2018, the Company announced that it had entered into a letter of intent with Grey Wolf Animal Health Inc. (“Grey Wolf”) to develop cannabis products to support the well-being of pets. Grey Wolf is a specialty animal health company focused on developing, acquiring and in-licensing companion animal health products for the Canadian and global markets. It is intended that CannTrust’s expertise in medical cannabis will be combined with Grey Wolf’s veterinary experience, giving pet owners a trusted avenue to support the well-being of their pets. Under the proposed terms of the partnership, Grey Wolf and CannTrust will each be equal 50% shareholders in a newly created joint venture company. In addition, pursuant to the letter of intent, CannTrust Opco would receive warrants to acquire common shares of Grey Wolf which constitute a 29% equity interest in Grey Wolf (subject to dilution).

On April 18, 2018, the Company announced that it had entered into a letter of intent with Grey Wolf Animal Health Inc. ("Grey Wolf") to develop cannabis products to support the well-being of pets. Grey Wolf is a specialty animal health company focused on developing, acquiring and in-licensing companion animal health products for the Canadian and global markets. It is intended that CannTrust's expertise in medical cannabis will be combined with Grey Wolf's veterinary experience, giving pet owners a trusted avenue to support the well-being of their pets. Under the proposed terms of the partnership, Grey Wolf and CannTrust will each be equal 50% shareholders in a newly created joint venture company. In addition, pursuant to the letter of intent, CannTrust Opco would receive warrants to acquire common shares of Grey Wolf which constitute a 29% equity interest in Grey Wolf (subject to dilution). The Company and Grey Wolf have agreed to extend the letter of intent and expect to enter into a definitive agreement prior to June 30, 2018.

In June, the Company entered into a shareholder’s agreement with Grey Wolf Animal Health Inc. (“Grey Wolf”) to develop ground breaking cannabis products to support the well-being of pets. Under the terms of the partnership, Grey Wolf and CannTrust are equal partners in a newly created subsidiary of Grey Wolf. This is another step forward in our strategy to expand our best-in-class products and technology into adjacent categories and we look forward to launching industry leading, high quality, standardized cannabis products specifically designed for pets. Our Joint Venture with Stenocare in Denmark and our partnership with Grey Wolf are just the beginning of what we believe will be global and diversified market opportunities.

The revenues were generated from global sales of the Company’s legal hemp-based products for pets. Sales of the products totaled $652,370 (CAD), making it the Company’s third record-setting quarter in a row.

Yes, VCA has always supported the autonomy that veterinarians need in order to make the best decisions for our clients and their pets. This will continue to be a cornerstone of what makes VCA a great place to work for veterinarians and the entire veterinary team.

As a world-leading pet care provider and a business within Mars, Mars Petcare is committed to attracting, developing and retaining the best veterinarians in the world, and supporting them in their efforts to provide leading-edge delivery of healthcare to pets. Thirty-eight brands make up Mars Petcare’s portfolio and you may be familiar with many of them, including PEDIGREE®, CESAR®, WHISKAS®, SHEBA®, ROYAL CANIN®, GREENIES®, IAMS® and EUKANUBA®.

VCA joins Mars Petcare, one of the world’s leading pet care providers. Pet care has been an important part of Mars for over 80 years. The transaction reaffirms Mars’ commitment to the pet care industry and the veterinary profession, and once completed will help drive Mars Petcare’s purpose to create A Better World for Pets. Mars Petcare’s portfolio of Veterinary Services businesses includes BANFIELD® Pet Hospital, BLUEPEARL® and PET PARTNERSTM. Together with VCA, these businesses will provide an unprecedented level of access to high quality veterinary care for pets, from wellness and prevention to primary, emergency and specialty care. Mars Petcare is already an industry leader in pet nutrition with global brands that include ROYAL CANIN®, PEDIGREE® and WHISKAS®. Mars has a growing business in pet DNA testing through the WISDOM PANEL®, and in 2015 also acquired pet technology provider WHISTLE.

Hemp is a variety of cannabis and although it has been around for centuries, we’ve only just started to recognize its potential uses for people and pets. At the same time, the rules are changing around cannabis in Canada and the U.S., and we at True Leaf see the opportunity to research and develop new hemp and cannabis products that serve the health and wellness for both people and pets.